Closed System Drug Transfer Device Market

Key Players: Baxter International Inc (US), B. Braun Melsungen AG (DE), Calea (GB), ICU Medical Inc (US), Corvida Medical (US), Equashield LLC (US), Teva Pharmaceutical Industries Ltd (IL), Fresenius Kabi AG (DE), McKesson Corporation (US)

Closed System Drug Transfer Device Market

Closed System Drug Transfer Device Market Research Report Information By type (Membrane to Membrane and Needleless System), By Component (Vial Access Devices, Syringe Safety Devices, Accessories, Bag/Line Access Devices), By Closing Mechanism (Push to Turn System, Color-to-color Alignment System, Leur Lock Systems, Click to Lock Systems), By Technology (Compartmentalize Devices, Diaphragm-Based Devices, and Air Filtration Devices) By End-Users (Hospitals & Clinics, Specialty Centers, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
ID: MRFR/HC/6264-CR
146 Pages
Vikita Thakur, Rahul Gotadki
Last Updated: May 15, 2026
Request Free Sample

Closed System Drug Transfer Device Market Summary

As per Market Research Future analysis, the Closed System Drug Transfer Device Market was estimated at 1.2 USD Billion in 2024. The Closed System Drug Transfer Device industry is projected to grow from USD 1.322 Billion in 2025 to USD 3.483 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.1% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Closed System Drug Transfer Device Market is poised for substantial growth driven by technological advancements and increasing safety awareness.

  • North America remains the largest market for closed system drug transfer devices, reflecting a strong emphasis on regulatory compliance and safety standards.
  • The Asia-Pacific region is emerging as the fastest-growing market, driven by rising healthcare investments and an expanding patient population.
  • Membrane-to-membrane systems dominate the market, while needleless systems are experiencing rapid growth due to their enhanced safety features.
  • Technological innovations and an increased focus on occupational health are key drivers propelling the demand for closed system drug transfer devices.

Market Size & Forecast

2024 Market Size 1.2 (USD Billion)
2035 Market Size 3.483 (USD Billion)
CAGR (2025 - 2035) 10.17%

Major Players

Baxter International Inc (US), B. Braun Melsungen AG (DE), Calea (GB), ICU Medical Inc (US), Corvida Medical (US), Equashield LLC (US), Teva Pharmaceutical Industries Ltd (IL), Fresenius Kabi AG (DE), McKesson Corporation (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Closed System Drug Transfer Device Market Trends

The Closed System Drug Transfer Device Market is currently experiencing a notable evolution, driven by increasing awareness regarding safety protocols in healthcare settings. This market encompasses devices designed to prevent contamination during the handling of hazardous drugs, thereby safeguarding healthcare professionals and patients alike. As regulatory bodies emphasize stringent safety measures, the demand for these devices appears to be on the rise. Furthermore, advancements in technology are likely to enhance the functionality and efficiency of these systems, making them more appealing to healthcare providers. In addition, the growing prevalence of chronic diseases necessitates the need for effective drug delivery systems, which may further propel the Closed System Drug Transfer Device Market. The integration of innovative designs and user-friendly features could potentially attract a broader range of users, from hospitals to outpatient facilities. As the market continues to evolve, it seems poised for substantial growth, reflecting the ongoing commitment to improving safety standards in drug administration. Stakeholders in this sector must remain vigilant to emerging trends and adapt accordingly to maintain a competitive edge.

Technological Advancements

The Closed System Drug Transfer Device Market is witnessing a surge in technological innovations. New designs and materials are being developed to enhance safety and usability. These advancements may lead to more efficient drug transfer processes, reducing the risk of exposure to hazardous substances.

Regulatory Compliance

Increasing regulatory scrutiny is shaping the Closed System Drug Transfer Device Market. Healthcare facilities are compelled to adhere to stringent safety guidelines, which may drive the adoption of these devices. Compliance with regulations could become a key factor influencing purchasing decisions.

Rising Awareness of Safety

There is a growing awareness regarding the importance of safety in drug handling. This trend is likely to boost the demand for Closed System Drug Transfer Devices as healthcare professionals seek to minimize risks associated with hazardous drug exposure. Enhanced education and training may further support this shift.

Closed System Drug Transfer Device Market Drivers

Regulatory Compliance

Regulatory compliance plays a crucial role in shaping the Closed System Drug Transfer Device Market. Governments and health organizations are implementing stringent guidelines to ensure the safe handling of hazardous drugs. Compliance with these regulations is not only mandatory but also enhances the credibility of healthcare providers. The market is influenced by the need for devices that meet these regulatory standards, which can lead to increased adoption rates. As a result, manufacturers are focusing on developing products that align with these regulations, thereby driving growth in the Closed System Drug Transfer Device Market.

Rising Demand for Safety

The rising demand for safety in healthcare settings is a significant driver for the Closed System Drug Transfer Device Market. Healthcare professionals are increasingly aware of the risks associated with handling hazardous drugs, leading to a greater emphasis on safety protocols. This heightened awareness is prompting hospitals and clinics to invest in closed system devices that minimize the risk of contamination and exposure. Market data indicates that the demand for these devices is expected to rise, with a projected increase in sales by 20% over the next few years. This trend underscores the importance of safety in the Closed System Drug Transfer Device Market.

Technological Innovations

The Closed System Drug Transfer Device Market is experiencing a surge in technological innovations that enhance safety and efficiency in drug handling. Advanced designs, such as needle-free systems and automated transfer devices, are being developed to minimize the risk of exposure to hazardous drugs. These innovations not only improve user experience but also comply with stringent safety regulations. The market is projected to grow at a compound annual growth rate of approximately 15% over the next five years, driven by these advancements. As healthcare facilities increasingly adopt these technologies, the Closed System Drug Transfer Device Market is likely to witness significant expansion.

Expansion of Oncology Treatments

The expansion of oncology treatments is significantly influencing the Closed System Drug Transfer Device Market. As the prevalence of cancer continues to rise, there is an increasing need for safe and effective drug delivery systems. Closed system drug transfer devices are essential in oncology settings, where the handling of cytotoxic drugs poses substantial risks. Market analysts project that the oncology segment will account for a considerable share of the Closed System Drug Transfer Device Market, with growth rates expected to exceed 18% in the coming years. This trend highlights the critical role of these devices in ensuring safe drug administration in oncology.

Increased Focus on Occupational Health

An increased focus on occupational health within healthcare environments is driving the Closed System Drug Transfer Device Market. Healthcare workers are at risk of exposure to hazardous drugs, which can lead to serious health issues. As organizations prioritize the well-being of their staff, there is a growing demand for closed system drug transfer devices that protect healthcare professionals from potential harm. This shift in focus is likely to result in a substantial increase in the adoption of these devices, contributing to the overall growth of the Closed System Drug Transfer Device Market.

Market Segment Insights

By Type: Membrane-To-Membrane Systems (Largest) vs. Needleless Systems (Fastest-Growing)

In the Closed System Drug Transfer Device Market, Membrane-To-Membrane Systems hold the largest market share, attributed to their efficiency and safety in transferring hazardous drugs. This segment has established a strong foothold due to robust demand from healthcare facilities aiming to reduce the risk of contamination during drug preparation. In contrast, Needleless Systems are gaining traction, appealing to providers focused on minimizing needle stick injuries and enhancing patient safety. Their share is increasing as healthcare institutions adopt innovative methods to streamline procedures and improve safety protocols.

Type: Membrane-To-Membrane Systems (Dominant) vs. Needleless Systems (Emerging)

Membrane-To-Membrane Systems are at the forefront of the Closed System Drug Transfer Device Market, characterized by their specialized design that ensures secure drug transfer while minimizing the risk of exposure. These systems are preferred in hospitals and oncology settings, where safety is paramount. On the other hand, Needleless Systems are emerging as a preferred alternative due to their ability to eliminate the use of needles, which significantly reduces the risk of needlestick injuries. As more healthcare providers focus on safety and efficiency, the demand for Needleless Systems is rapidly increasing, indicating a shift towards more innovative and user-friendly drug delivery methods.

By Component: Vial Access Devices (Largest) vs. Syringe Safety Devices (Fastest-Growing)

In the Closed System Drug Transfer Device Market, the Component segment encompasses a variety of devices designed to enhance safety and efficiency in drug handling. Vial Access Devices hold the largest market share, driven by their established use in hospitals and pharmacies for safe drug preparation and transfer. On the other hand, Syringe Safety Devices are quickly gaining traction, representing the fastest-growing segment due to increasing awareness of needle-stick injuries and the demand for safer healthcare practices among medical professionals. The growth of the Component segment is associated with advancements in technology and the rising focus on patient safety and workplace safety regulations. As healthcare providers continue to prioritize the reduction of contamination risks and increase medication safety, the demand for both Vial Access and Syringe Safety Devices is expected to rise. Bag/Line Access Devices and Accessories are also important, although they presently occupy a smaller share. Innovations in product design and functionality are anticipated to drive future growth across all components of this segment.

Vial Access Devices (Dominant) vs. Syringe Safety Devices (Emerging)

Vial Access Devices serve as the cornerstone of the Closed System Drug Transfer Device Market, providing safe access to medications while minimizing contamination risks. Their dominant position is bolstered by decades of usage in various healthcare settings, ensuring reliability and trust among practitioners. The introduction of advanced features, such as enhanced sterility and user-friendly mechanisms, keeps these devices at the forefront of the market. Conversely, Syringe Safety Devices are emerging as a critical component due to their potential to significantly reduce needle-stick injuries, a prevalent issue in healthcare environments. The growing emphasis on patient and healthcare worker safety has fueled innovation in this area, resulting in an array of devices designed with safety-engineering principles. As more healthcare facilities adapt to regulatory pressures and safety standards, the popularity of Syringe Safety Devices is set to expand, marking a notable trend in the industry.

By Closing Mechanism: Push To Turn System (Largest) vs. Click-To Lock System (Fastest-Growing)

In the Closed System Drug Transfer Device Market, the Push To Turn System currently stands as the largest segment, commanding significant market share due to its robust design and ease of use in healthcare settings. Following closely is the Color-To-Color Alignment System, which has carved out a notable presence by ensuring safety and reducing errors during drug transfers. Other systems like Luer Lock and Click-To Lock represent a smaller share but are crucial for specific applications, illustrating a varied landscape in closing mechanisms.

Push To Turn System (Dominant) vs. Click-To Lock System (Emerging)

The Push To Turn System is recognized for its reliability and user-friendly operation, making it the preferred choice among healthcare professionals. It excels in providing secure connections for drug transfer, promoting patient safety and minimizing contamination risks. On the other hand, the Click-To Lock System is emerging rapidly due to its innovative design, ensuring a quick and secure fit that appeals to modern healthcare practices. Its growing adoption is driven by the push for efficiency and safety in drug handling, making it a significant contender as healthcare facilities seek advanced solutions.

By Technology: Diaphragm-Based Devices (Largest) vs. Compartmentalize Devices (Fastest-Growing)

In the Closed System Drug Transfer Device Market, Diaphragm-Based Devices hold the largest share due to their proven efficacy in preventing contamination during drug transfer. This type of device is widely adopted in healthcare settings, which enhances its market presence. Compartmentalize Devices, on the other hand, are gaining traction with increased focus on safety and efficiency, contributing to their rapid market growth. Their innovative designs appeal to healthcare providers looking for enhanced functionality and safety features. The growth of Diaphragm-Based Devices is supported by the rising number of regulations around drug safety and preparation, which drive adoption rates. In contrast, Compartmentalize Devices are emerging as the fastest-growing segment, with advancements in technology enhancing their usability. The increasing prevalence of hazardous drug handling in healthcare also propels demand for both device types, as institutions prioritize protecting healthcare workers and ensuring compliant drug transfer processes.

Technology: Diaphragm-Based Devices (Dominant) vs. Compartmentalize Devices (Emerging)

Diaphragm-Based Devices continue to dominate the Closed System Drug Transfer Device Market due to their reliability and safety profile. These devices feature robust designs that minimize risks associated with harmful drug exposure, making them a preferred choice for healthcare institutions. In contrast, Compartmentalize Devices are viewed as an emerging alternative, providing innovative solutions that optimize drug transfer processes. Their unique structures lead to enhanced containment capability and operational efficiency, appealing to operators focused on decreasing contamination risks. While Diaphragm-Based Devices are established in the market, the increasing adoption of Compartmentalize Devices indicates a shifting landscape, where safety and advanced technology play crucial roles in shaping healthcare delivery.

By End User: Hospitals & Clinics (Largest) vs. Specialty Centers (Fastest-Growing)

In the Closed System Drug Transfer Device Market, the distribution of market share among end users reveals that Hospitals and Clinics hold a significant proportion, serving as the backbone of healthcare delivery. This segment benefits from a wide range of pharmaceutical services and a higher frequency of drug transfers, primarily due to the acute care needs of patients. Specialty Centers, while smaller in overall share, are rapidly gaining traction due to their focused services and specialized treatments that necessitate the use of closed system transfer devices. The growth trends in the end user segment are primarily driven by an increasing emphasis on safety protocols in hospitals and clinics, pushing the adoption of closed system devices to mitigate exposure to hazardous drugs. Additionally, the rise in specialty centers, particularly in fields like oncology and infusion therapy, contributes to the market's expansion as they prioritize patient safety and efficacy in drug delivery systems The innovative development of these devices is a key factor that is expected to sustain growth in both segments, especially as regulations become more stringent.

Hospitals & Clinics (Dominant) vs. Specialty Centers (Emerging)

Hospitals and Clinics remain the dominant force in the Closed System Drug Transfer Device Market due to their extensive infrastructure and the volume of drug transfers conducted daily. These facilities are often the primary adopters of new technologies, including closed system devices, to enhance safety protocols and comply with regulatory standards. On the other hand, Specialty Centers, which offer focused services such as chemotherapy and chronic disease management, represent an emerging market segment. They are characterized by their tailored approach to treatment and a higher need for specialized drug transfer systems. This growing recognition of the unique needs of Specialty Centers drives innovation and development, positioning them as pivotal contributors to the market's evolution.

Get more detailed insights about Closed System Drug Transfer Device Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for Closed System Drug Transfer Devices (CSTD), holding approximately 45% of the global market share. The region's growth is driven by stringent regulatory frameworks, increasing awareness of safety protocols, and a rising incidence of hazardous drug exposure among healthcare workers. The demand for advanced drug delivery systems is further fueled by the growing prevalence of chronic diseases and the need for efficient healthcare solutions. The United States is the primary contributor to this market, with key players like Baxter International Inc, ICU Medical Inc, and McKesson Corporation leading the competitive landscape. The presence of established healthcare infrastructure and significant investments in R&D enhance the region's market position. Additionally, the focus on improving patient safety and compliance with regulations continues to drive innovation in CSTD technologies.

Europe : Regulatory Frameworks Drive Growth

Europe is the second-largest market for Closed System Drug Transfer Devices, accounting for approximately 30% of the global share. The region's growth is propelled by increasing regulatory requirements aimed at ensuring the safety of healthcare professionals and patients. The European Medicines Agency (EMA) has implemented guidelines that mandate the use of CSTDs in specific healthcare settings, further boosting market demand. Leading countries in this region include Germany, France, and the United Kingdom, where major players like B. Braun Melsungen AG and Fresenius Kabi AG are actively involved. The competitive landscape is characterized by a mix of established companies and innovative startups, focusing on developing advanced CSTD solutions. The emphasis on patient safety and compliance with stringent regulations continues to shape the market dynamics in Europe.

Asia-Pacific : Rapid Growth and Adoption

Asia-Pacific is witnessing rapid growth in the Closed System Drug Transfer Device Market, driven by increasing healthcare expenditures and a rising awareness of safety protocols. The region holds approximately 20% of the global market share, with countries like China and India leading the charge. The growing prevalence of chronic diseases and the expansion of healthcare infrastructure are significant factors contributing to this growth. China is emerging as a key player in the CSTD market, with local manufacturers and international companies like Teva Pharmaceutical Industries Ltd and Corvida Medical expanding their presence. The competitive landscape is evolving, with a focus on innovation and affordability. As regulatory bodies in the region begin to implement stricter safety guidelines, the demand for CSTDs is expected to rise significantly, further enhancing market opportunities.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the Closed System Drug Transfer Device Market, holding about 5% of the global share. The growth is primarily driven by increasing healthcare investments and a rising focus on patient safety. Governments in the region are beginning to recognize the importance of implementing safety measures in healthcare settings, which is expected to catalyze market growth in the coming years. Countries like South Africa and the UAE are at the forefront of this development, with a growing number of healthcare facilities adopting CSTDs. The competitive landscape is still developing, with opportunities for both local and international players to establish a foothold. As awareness of hazardous drug exposure increases, the demand for CSTDs is anticipated to grow, presenting significant opportunities for market expansion.

Closed System Drug Transfer Device Market Regional Image

Key Players and Competitive Insights

The Closed System Drug Transfer Device Market is currently characterized by a dynamic competitive landscape, driven by increasing regulatory scrutiny and a heightened focus on safety in drug handling. Key players are actively pursuing strategies that emphasize innovation, regional expansion, and strategic partnerships to enhance their market positioning. For instance, Baxter International Inc (US) has been focusing on expanding its product portfolio through technological advancements, while B. Braun Melsungen AG (DE) is leveraging its strong global presence to penetrate emerging markets. These strategies collectively contribute to a competitive environment that is increasingly shaped by the need for enhanced safety protocols and efficient drug delivery systems. In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market structure appears moderately fragmented, with several players vying for market share. This fragmentation is indicative of a competitive environment where innovation and operational efficiency are paramount. The collective influence of key players, such as ICU Medical Inc (US) and Corvida Medical (US), is significant, as they continuously adapt to market demands and regulatory changes, thereby shaping the overall market dynamics. In August 2025, ICU Medical Inc (US) announced the launch of a new line of closed system drug transfer devices designed to enhance safety and efficiency in drug preparation. This strategic move is likely to bolster the company’s market share by addressing the growing demand for safer drug handling solutions. The introduction of this product line not only reflects ICU Medical's commitment to innovation but also positions the company favorably against competitors who may not have similar offerings. In September 2025, Corvida Medical (US) entered into a strategic partnership with a leading pharmaceutical company to co-develop advanced closed system drug transfer devices. This collaboration is expected to leverage both companies' strengths, potentially leading to enhanced product offerings and improved market penetration. Such partnerships are indicative of a trend where companies are seeking synergies to accelerate product development and meet evolving regulatory standards. Furthermore, in July 2025, B. Braun Melsungen AG (DE) expanded its manufacturing capabilities in Asia to better serve the growing demand in that region. This expansion is strategically important as it not only enhances the company’s operational efficiency but also positions it to capitalize on the increasing market opportunities in Asia. By localizing production, B. Braun is likely to reduce costs and improve supply chain reliability, which is crucial in a market where timely delivery is essential. As of October 2025, the competitive trends in the Closed System Drug Transfer Device Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the need to collaborate to innovate and meet regulatory demands. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological innovation, enhanced safety features, and supply chain reliability. This shift suggests that companies that prioritize these aspects will likely gain a competitive edge in the market.

Key Companies in the Closed System Drug Transfer Device Market include

Industry Developments

December 2023: Equashield announced the launch of its latest product, the Mundus Mini HD. Leveraging Equashield’s CSTDs, the Mundus Mini HD aims to minimize contamination, exposure, and errors, thereby enhancing compounding safety and efficiency.

October 2023: The EQUASHIELD Syringe Unit has received additional FDA clearance for full volume use.

April 2022: Simplivia has launched Chemfort, its latest closed system transfer device (CSTD). Chemfort is designed to significantly minimize the risk of exposure for healthcare professionals during the preparation and administration of hazardous drugs.

December 2021: B. Braun SE introduced the next generation OnGuard 2 CSTD in the US. Building on the strengths of its predecessor, OnGuard 2 incorporates upgraded materials and enhanced features aimed at improving usability while retaining all the existing advantages of the original OnGuard device.

Future Outlook

Closed System Drug Transfer Device Market Future Outlook

The Closed System Drug Transfer Device Market is projected to grow at a 10.17% CAGR from 2025 to 2035, driven by increasing safety regulations and rising demand for oncology drugs.

New opportunities lie in:

  • Development of integrated telehealth solutions for remote drug administration.
  • Expansion into emerging markets with tailored product offerings.
  • Partnerships with pharmaceutical companies for co-branded drug delivery systems.

By 2035, the market is expected to achieve substantial growth, solidifying its position as a critical component in healthcare.

Market Segmentation

Closed System Drug Transfer Device Market Type Outlook

  • Membrane-To-Membrane Systems
  • Needleless Systems

Closed System Drug Transfer Device Market End User Outlook

  • Hospitals & clinics
  • Specialty centers
  • Others

Closed System Drug Transfer Device Market Component Outlook

  • Vial Access Devices
  • Syringe Safety Devices
  • Bag/Line Access Devices
  • Accessories

Closed System Drug Transfer Device Market Technology Outlook

  • Compartmentalize Devices
  • Diaphragm-Based Devices
  • Air Filtration Devices

Closed System Drug Transfer Device Market Closing Mechanism Outlook

  • Push To Turn System
  • Color-To-Color Alignment System
  • Luer Lock Systems
  • Click-To Lock System

Report Scope

MARKET SIZE 2024 1.2(USD Billion)
MARKET SIZE 2025 1.322(USD Billion)
MARKET SIZE 2035 3.483(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 10.17% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Baxter International Inc (US), B. Braun Melsungen AG (DE), Calea (GB), ICU Medical Inc (US), Corvida Medical (US), Equashield LLC (US), Teva Pharmaceutical Industries Ltd (IL), Fresenius Kabi AG (DE), McKesson Corporation (US)
Segments Covered type, Component, Closing Mechanism, Technology, End-Users, Region
Key Market Opportunities Advancements in safety regulations drive demand for innovative Closed System Drug Transfer Device Market solutions.
Key Market Dynamics Rising regulatory scrutiny and technological advancements drive innovation in the Closed System Drug Transfer Device market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Closed System Drug Transfer Device Market by 2035?

The market is projected to reach approximately 3.483 USD Billion by 2035.

What was the market valuation of the Closed System Drug Transfer Device Market in 2024?

The market valuation was 1.2 USD Billion in 2024.

What is the expected CAGR for the Closed System Drug Transfer Device Market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 10.17%.

Which companies are considered key players in the Closed System Drug Transfer Device Market?

Key players include Baxter International Inc, B. Braun Melsungen AG, and ICU Medical Inc, among others.

What are the main types of Closed System Drug Transfer Devices and their market values?

Membrane-To-Membrane Systems and Needleless Systems each had a market value of 0.6 USD Billion in 2024, projected to grow to 1.74 and 1.743 USD Billion respectively by 2035.

What components are included in the Closed System Drug Transfer Device Market?

Components include Vial Access Devices, Syringe Safety Devices, and Bag/Line Access Devices, with projected values of 1.4, 1.03, and 0.69 USD Billion respectively by 2035.

What closing mechanisms are utilized in Closed System Drug Transfer Devices?

The market includes Push To Turn Systems and Luer Lock Systems, both expected to reach 0.99 USD Billion by 2035.

What technologies are driving the Closed System Drug Transfer Device Market?

Technologies such as Compartmentalize Devices and Diaphragm-Based Devices are projected to grow to 1.44 and 1.08 USD Billion respectively by 2035.

Who are the primary end users of Closed System Drug Transfer Devices?

Primary end users include hospitals and clinics, which are expected to grow to 1.75 USD Billion by 2035.

How does the market for Closed System Drug Transfer Devices compare across different segments?

The market shows varied growth across segments, with hospitals and clinics leading, followed by specialty centers and others, indicating diverse applications.
Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch
Leave a Comment

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical and pharmaceutical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), US Pharmacopeia (USP) General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings, Occupational Safety and Health Administration (OSHA), National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention (CDC), International Society of Oncology Pharmacy Practitioners (ISOPP), American Society of Health-System Pharmacists (ASHP), Oncology Nursing Society (ONS), European Society of Oncology Pharmacy (ESOP), International Agency for Research on Cancer (IARC), World Health Organization (WHO) International Agency for Research on Cancer, National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, Health Resources and Services Administration (HRSA), EU OSHA European Risk Observatory Database, and national health ministry reports from key oncology markets. These sources were used to collect hazardous drug handling regulations, CSTD regulatory approval data, clinical safety studies, oncology treatment statistics, healthcare worker exposure incidents, and market landscape analysis for membrane-to-membrane systems, needleless systems, vial access devices, syringe safety devices, and other CSTD technologies.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. From pharmaceutical compounding equipment suppliers, medical device OEMs, and CSTD manufacturers, supply-side sources comprised CEOs, VPs of Product Development, regulatory affairs chiefs, quality assurance directors, and commercial directors. Demand-side sources included nursing managers from oncology units, procurement leads from hospital systems, cancer center administrators, infusion center medical directors from academic medical centers, community hospitals, and specialty oncology clinics, pharmacy directors, and hospital safety officers. Additionally, board-certified oncology pharmacists and pharmacy directors. The primary research validated market segmentation, confirmed product lifecycle timelines, and collected insights on clinical adoption patterns, USP <800> compliance strategies, pricing dynamics, and group purchasing organization (GPO) contracting trends.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (38%), Europe (29%), Asia-Pacific (25%), Rest of World (8%)

Market Size Estimation

Global market valuation was derived through revenue mapping and device deployment analysis. The methodology included:

Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across membrane-to-membrane systems, needleless systems, vial access devices, syringe safety devices, bag/line access devices, and accessories

Analysis of reported and modeled annual revenues specific to CSTD portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (hazardous drug handling volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.